Kurs & Likviditet
Kalender
| 2025-04-24 | Årsstämma |
| 2025-02-26 | Bokslutskommuniké 2024 |
| 2024-08-30 | Kvartalsrapport 2024-Q2 |
| 2024-04-12 | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2024-04-11 | Årsstämma |
| 2024-02-28 | Bokslutskommuniké 2023 |
| 2023-08-31 | Kvartalsrapport 2023-Q2 |
| 2023-04-27 | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2023-04-26 | Årsstämma |
| 2023-02-28 | Bokslutskommuniké 2022 |
| 2022-08-31 | Kvartalsrapport 2022-Q2 |
| 2022-04-29 | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2022-04-28 | Årsstämma |
| 2022-03-01 | Bokslutskommuniké 2021 |
| 2021-11-18 | 15-10 2021-Q3 |
| 2021-08-26 | Kvartalsrapport 2021-Q2 |
| 2021-05-26 | Kvartalsrapport 2021-Q1 |
| 2021-04-28 | Årsstämma |
| 2021-04-16 | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2021-03-22 | Extra Bolagsstämma 2021 |
| 2021-02-18 | Bokslutskommuniké 2020 |
| 2020-11-19 | Kvartalsrapport 2020-Q3 |
| 2020-10-21 | Extra Bolagsstämma 2020 |
| 2020-08-27 | Kvartalsrapport 2020-Q2 |
| 2020-06-11 | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2020-06-10 | Årsstämma |
| 2020-05-26 | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | Bokslutskommuniké 2019 |
| 2019-11-19 | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | Kvartalsrapport 2019-Q1 |
| 2019-04-26 | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2019-04-25 | Årsstämma |
| 2019-02-18 | Extra Bolagsstämma 2019 |
| 2018-08-22 | Kvartalsrapport 2018-Q2 |
| 2018-05-31 | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2018-05-30 | Årsstämma |
| 2018-05-30 | Kvartalsrapport 2018-Q1 |
| 2018-02-27 | Bokslutskommuniké 2017 |
| 2017-12-20 | Extra Bolagsstämma 2017 |
| 2017-11-22 | Kvartalsrapport 2017-Q3 |
| 2017-08-23 | Kvartalsrapport 2017-Q2 |
| 2017-05-26 | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2017-05-24 | Kvartalsrapport 2017-Q1 |
| 2017-05-24 | Årsstämma |
| 2017-02-28 | Bokslutskommuniké 2016 |
| 2016-11-23 | Kvartalsrapport 2016-Q3 |
| 2016-10-12 | Extra Bolagsstämma 2016 |
| 2016-08-24 | Kvartalsrapport 2016-Q2 |
| 2016-05-31 | Kapitalmarknadsdag 2016 |
| 2016-05-20 | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2016-05-19 | Årsstämma |
| 2016-05-19 | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | Bokslutskommuniké 2015 |
| 2015-11-17 | Kapitalmarknadsdag 2015 |
| 2015-10-21 | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | Kvartalsrapport 2015-Q2 |
| 2015-05-27 | Kvartalsrapport 2015-Q1 |
| 2015-03-09 | Årsstämma |
| 2014-11-12 | Extra Bolagsstämma 2014 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Oslo, Norway, 21 February 2023
Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the second half and full year 2022 on Tuesday, 28 February 2023.
A presentation by Nordic Nanovector's interim CEO & CFO, Ludvik Sandnes, will be held in-person and webcast live beginning at 8:30am CET.
VENUE: ADVOKATFIRMAET CLP DA, Sommerrogata 13, 0255 Oslo
Questions can be submitted in advance to ir@nordicnanovector.com
The webcast can be accessed from www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event.
The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2022 from 7:00am CET the same day.
IR enquiries
Ludvik Sandnes, Interim CEO & CFO
+47 907 43 017
ir@nordicnanovector.com
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.
Further information can be found at www.nordicnanovector.com (https://nam10.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.nordicnanovector.com%2F&data=05%7C01%7Cmark.swallow%40medistrava.com%7C0b5d55887fcc4bddd24108db03d8d2c1%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7C0%7C638108002017583559%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=8ttx4sNkxIXKbRtEA7RQp%2FvHln24QCaKkOEaehniofM%3D&reserved=0)
This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.